Apply For A Research Grant

ICRF’S ONLINE APPLICATION SYSTEM IS NOW CLOSED FOR THE 2024-2025 FUNDING YEAR.

ICRF stands with Israel and hopes that peace will come back to its citizens soon.

We expect to open the online application system again in the Fall for the 2025-2026 funding year.

To access ProposalCentral:

Click Here


Please note:

  • This online application system was instituted in 2020. If you created a user account prior to 2020, it no longer exists and you now must create a new one.
  • Israel Cancer Research Fund (ICRF) supports basic, translational, and clinical cancer research. All research must be conducted in Israel, except in the case of clearly-identified, international collaborative grants. To apply for an ICRF grant, an investigator must be a citizen of Israel (proof of Israeli citizenship must be furnished upon request).
  • The Postdoctoral Fellowship grant category has been discontinued. Funding will be continued for researchers previously awarded Postdoctoral Fellowships (2022 and earlier) until completed.
  • ICRF funds cannot be used for salary of the PI or Co-Investigators, for clerical or other administrative expenses, for overhead charges, or for work performed outside of Israel. However, for CRCDA applicants only, partial salary support may be requested for the PI.
  • ICRF has adopted a new process for Research Professorship grant applications, with 3 components: (1) Apply for a 3-year Project Grant; (2) Include a statement outlining the anticipated scientific goals and trajectory for 2 additional years of funding, if a Research Professorship grant is awarded; and (3) Provide a statement describing the accomplishments and achievements that make you especially qualified for a prestigious ICRF Research Professorship grant. (See below for more information.)
  • The Barbara S. Goodman Endowed RCDA in Pancreatic Cancer is available for new applications. To apply, please create a new RCDA application in ProposalCentral and select “yes” where indicated on the “Project Title” page.
  • The Beverly Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers is once again available for new applications.
  • A Special Initiative in Neuroblastoma Research is also available in the Project Grant category.

To View, Save, or Print the most recent General Policies Governing ICRF Grants, Click Here

Details on the ICRF grant categories that were open for new applications for the 2024-2025 funding year are listed below:

BEVERLEY LIBRACH ABSHEZ INITIATIVE FOR OVARIAN AND FEMALE REPRODUCTIVE SYSTEM CANCERS

Graciously sponsored by an anonymous donor, the Beverley Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers has been established to advance our understanding of gynecologic cancers and thereby limit the burden of these diseases.  Gynecological cancers are tumors that initiate in the female reproductive organs, and include cervical, ovarian, uterine, vaginal, vulvar, and fallopian tube cancer.  Each gynecologic cancer is unique, with different signs and symptoms, different risk factors, and different prevention strategies.  All women are at risk for gynecologic cancers, and the risk increases with age.  While cervical cancer is readily detected early, when treatment can be most effective, reliable tests for other gynecological cancers are not yet available, and ovarian cancer ranks fifth in cancer deaths among women.  The Abshez Initiative supports research that identifies risk factors, develops preventive strategies, improves detection technologies, and devises new strategies for prevention, detection, and treatment of gynecologic cancers. Abshez Initiative grants will be awarded for two (2) years for $100,000 per year, as determined by the Scientific Review Panel and the availability of funds.  It is anticipated that two (2) grants will be awarded. 

To View, Save, or Print the Abshez Initiative Grant Policies, click here

RESEARCH PROFESSORSHIP GRANTS

ICRF Research Professorship grants recognize accomplished investigators whose research has significant impact on our understanding of cancer, and whose extended commitment to fundamental issues in cancer are an inspiration to others — scientists and non-scientists alike.  Evaluation of Research Professorship grant applications will take into account scientific achievements, future plans, and accomplishments that particularly qualify the investigator for a Research Professorship. Applicants must hold the rank of Full Professor or equivalent and must have carried out research for at least eight years since receiving the PhD, MD, or MD/PhD degree. Those awarded ICRF Research Professorships are requested to use the title “ICRF Research Professor” as appropriate in professional appearances and publications, and to plan to act on occasion as spokespersons for the ICRF and for cancer research, by speaking about their research and their careers in cancer research at times arranged to be mutually convenient for the grantee and the ICRF. Research Professorship funding may be renewed.  This requires submission of a renewal application for competitive evaluation. To apply, please create a new Project Grant application in ProposalCentral and check the appropriate box to signify that you would also like to be considered for a Research Professorship grant where indicated on the “Project Title” page. The Project Grant application will undergo competitive review along with other Project Grant applications.  If the Project Grant application receives a competitive priority score, but the Research Professorship application is not funded, the Project Grant will be funded for 3 years at $60,000 per year (depending upon availability of funds). If the Research Professorship grant is funded, the Project Grant application will be withdrawn. Research Professorship grants are funded for five (5) years at a maximum stipend of $100,000 per year, as determined by the Scientific Review Panel and the availability of funds. 

To View, Save, or Print the Research Professorship Grant Policies, click here

ACCELERATION GRANTS

The mission of the ICRF is to support world-class research of high scientific merit and clear potential significance for advancing the understanding, diagnosis, or treatment of cancer. Some of the most exciting science does not start out with eventual success assured, but emerges from a high-risk/high-yield project carried out by creative and dedicated investigators. Acceleration Grants encourage innovative approaches by investigators pioneering new ways of addressing significant questions. While preliminary data are not required, they are useful in evaluating an application. ICRF Acceleration Grants are intended to support the research of established investigators. The grant is made to an institution with the understanding that it will support a specific project under the direction of a designated principal investigator. ICRF support under this grant category will only be given to Israeli institutions for work in Israel.  Awarded grants will be for a period of two (2) years, with a funding level of $70,000 per year.

In order to apply for the Acceleration Grants Category, a Letter of Intent (LOI) is required. The LOI should be submitted via ProposalCentral.  The deadline for LOI submission is: Thursday, November 30, 2023, 11:59PM EST.  A limited number of applicants whose Letters of Intent are deemed most meritorious will be invited to submit full research proposals and compete for the available grants. (Acceleration grants are not renewable.)

To View, Save, or Print the Acceleration Grant Policies, click here

CLINICAL RESEARCH CAREER DEVELOPMENT AWARDS (CRCDAs)

Clinical Research Career Development Awards (CRCDAs) are designed to enable early-career medical or pediatric oncologists with clear research potential to participate in mentored post-fellowship research training that will provide a strong foundation for a career in clinical research. CRCDAs are available to investigators in the formative phase of their careers who have demonstrated outstanding potential for contribution to clinical cancer research as independent investigators and who will benefit by additional mentored experience in a scientific environment that is conducive to the development of an independent research career. A candidate must have an MD degree and at least two years of fellowship training in oncology, including medical or pediatric hematology-oncology or a related oncologic specialty, but not more than five years of subsequent relevant professional experience prior to the start date of requested funding. CRCDAs are limited to a single support period of three (3) years at a maximum stipend of $45,000 per year. (CRCDAs are not renewable.)

To View, Save, or Print the CRCDA Policies, click here

RESEARCH CAREER DEVELOPMENT AWARDS (RCDAs)

Research Career Development Awards (RCDAs) are designed to enhance the research capabilities of young Israeli scientists in the formative phase of their careers who have demonstrated outstanding potential for contribution to cancer research as independent investigators. RCDAs are available to investigators with clear research potential who will benefit by additional mentored experience in a scientific environment that is conducive to the development of an independent research career. A candidate must have a doctoral degree and at least three (3) years of postdoctoral fellowship or equivalent experience, hold an independent junior position at an Israeli institution, and be within five (5) years of initial appointment to that position at the start date of requested funding. Awards are made for three (3) years at a maximum stipend of $45,000 per year. (RCDAs are not renewable.)

To View, Save, or Print the RCDA Policies, click here

BARBARA S. GOODMAN ENDOWED RCDA IN PANCREATIC CANCER

The Barbara S. Goodman Endowed Research Career Development Award for Pancreatic Cancer has been established as a special grant intended to advance our knowledge of the pathogenesis and treatment of pancreatic cancer. The Israel Cancer Research Fund (ICRF) invites Research Career Development Award (RCDA) applications from interested and eligible investigators studying the biology, diagnosis, treatment, supportive care, and/or prevention of cancer of the pancreas. ICRF RCDAs are designed to enhance the research capabilities of young Israeli scientists in the formative phase of their careers who have demonstrated outstanding potential for contribution to cancer research as independent investigators. RCDAs are available to investigators with clear research potential who will benefit by additional mentored experience in a scientific environment that is conducive to the development of an independent research career. A candidate must have a doctoral degree and at least three (3) years of postdoctoral fellowship or equivalent experience, hold an independent junior position at an Israeli institution, and be within five (5) years of initial appointment to that position at the start date of requested funding. Applications for the Goodman RCDA will be reviewed as a special category by our Scientific Review Panel, and the relationship of the research to pancreatic cancer must be defined in the application, but all RCDAs directed to this special program will also be considered in the general pool of RCDA applications so that, based on merit, more than one application may be funded. To apply for the Goodman RCDA, please create a new RCDA application in ProposalCentral and select “yes” where indicated on the “Project Title” page. Awards are made for three (3) years at a maximum stipend of $45,000 per year. (Goodman RCDAs are not renewable.)

To View, Save, or Print the Goodman Pancreatic Cancer RCDA Policies, click here

PROJECT GRANTS

Project Grants provide funding for projects of high scientific merit and clear potential significance for advancing the understanding, diagnosis, or treatment of cancer. Project Grants are intended to support the research of established investigators working in areas in which they have demonstrated expertise. The applicant must be an independent investigator who has demonstrated ability to lead a research team, as evident in the Biosketch and Publication Record. Multi-investigator applications and interdisciplinary approaches are encouraged, but not required. Applications must focus on questions related to human cancer that are supported by strong published or preliminary data and provide a solid foundation for future progress. Funding priority is typically given to projects with potential to impact prevention, diagnosis, or treatment of cancer in the next 5-10 years. Proposals that are high-risk/high-yield because they lack preliminary data, established resources, or depend on only a tenuous link to human cancer, should be submitted as Acceleration Grants, not Project Grants. Awards are made for three (3) years at a maximum stipend of $60,000 per year. (Current Project Grant recipients are encouraged to reapply for continued funding of the same project. Ideally, this should be done during the final year of the award so that, if selected, the new grant will begin upon completion of the old.)

To View, Save, or Print the Project Grant Policies, click here

SPECIAL INITIATIVE IN NEUROBLASTOMA RESEARCH

Israel Cancer Research Fund (ICRF) and Shir for Life (SFL) are pleased to issue a joint Request for Applications (RFA) for proposals in Neuroblastoma research. Projects must be headed by an Israeli PI, based in one of Israel’s research institutions (universities or hospitals). Proposals will be prioritized for funding based on their potential to contribute to the understanding, prevention, and effective treatment of neuroblastoma. To apply, please create a new Project Grant application in ProposalCentral and check the appropriate box to signify that you would also like to be considered for the Neuroblastoma Research RFA where indicated on the “Project Title” page. All applications directed to this special program will also be considered in the general pool of Project Grant applications so that, based on merit, more than one application may be funded. Funded proposals will be awarded for three (3) years at a maximum stipend of $60,000 per year.

To View, Save, or Print the Neuroblastoma Project Grant Policies, click here

~ RETURN TO TOP OF PAGE ~